Chandrakala Shanmukhaiah
Overview
Explore the profile of Chandrakala Shanmukhaiah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shah A, Kumar C, Shanmukhaiah C, Rajendran A, Mudaliar S, Idicula-Thomas S, et al.
Ann Hematol
. 2023 Jul;
102(10):2683-2693.
PMID: 37438490
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, genetic, autosomal recessive disorder characterized by severe thrombocytopenia, due to inefficient bone marrow megakaryopoiesis eventually leading to aplasia. Majority of the cases are...
12.
Setia P, Bargir U, Shanmukhaiah C, Jodhawat N, Gaikwad P, Vedpathak D, et al.
Br J Haematol
. 2023 May;
202(2):e11-e15.
PMID: 37199216
No abstract available.
13.
Vundinti B, Korgaonkar S, Dhangar S, Jijina F, Shanmukhaiah C
J Cancer Res Ther
. 2023 Apr;
19(2):340-346.
PMID: 37006070
Context: Chromosomal abnormalities play an important role in diagnosis and prognosis of hematological diseases. Aims: The aim of the present study was to study the pattern and frequency of chromosomal...
14.
Dhangar S, Shanmukhaiah C, Sawant L, Ghatanatti J, Shah A, Mathan S L, et al.
Cancer Genet
. 2023 Mar;
274-275:26-29.
PMID: 36965231
The sole t(8;22)(p11.2;q11.2)/BCR- FGFR1 chromosomal abnormality formerly known as aCML is an extremely rare disease entity with a history of rapid progression. Though patients resemble phenotypically chronic myeloid leukemia, the...
15.
Jimenez-Yuste V, Peyvandi F, Klamroth R, Castaman G, Shanmukhaiah C, Rangarajan S, et al.
Res Pract Thromb Haemost
. 2022 Nov;
6(8):e12837.
PMID: 36397934
Background: The bispecific monoclonal antibody emicizumab bridges activated factor IX and factor X, mimicking the cofactor function of activated factor VIII (FVIII), restoring hemostasis. Objectives: The Phase 3b STASEY study...
16.
Maurya N, Mohanty P, Panchal P, Shanmukhaiah C, Vundinti B
Mol Biol Rep
. 2022 Nov;
50(1):235-244.
PMID: 36322239
Background: Myelodysplastic syndromes (MDS) is defined as heterogenous disease, it contains heterogenous leukemic stem cells with various degree of cell differentiation. The perturbation of genes involved in myeloid progenitor cell...
17.
Maurya N, Mohanty P, Dhangar S, Panchal P, Jijina F, Mathan S, et al.
Sci Rep
. 2022 Apr;
12(1):5925.
PMID: 35396491
Myelodysplastic syndromes (MDS) are a group of clonal hematological disease with high risk of progression to AML. Accurate risk stratification is of importance for the proper management of MDS. Genetic...
18.
Chakrabarti P, George B, Shanmukhaiah C, Sharma L, Udupi S, Ghanima W
J Patient Rep Outcomes
. 2022 Mar;
6(1):24.
PMID: 35303181
Purpose: Immune thrombocytopenia (ITP) is primarily considered a bleeding disorder; its impact on patients' health-related quality of life (HRQoL) is under-recognized. We aimed to assess how aligned patient and physician...
19.
Kulkarni B, Ghargi K, Shanmukhaiah C, Shetty S
Front Med (Lausanne)
. 2022 Jan;
8:807664.
PMID: 35087851
Type 3 Von Willebrand Disease (VWD) is the least common but the most severe form of a disease, with a prevalence of about 0. 5 to 1 per million in...
20.
Shanmukhaiah C, Jijina F, Kannan S, Pai N, Kulkarni B, Khuba S, et al.
Haemophilia
. 2022 Jan;
28(2):286-291.
PMID: 35014121
Introduction: von Willebrand disease (VWD) is the common bleeding disorder with a clinically relevant bleeding prevalence of 1:10,000. von Willebrand disease patients lack both von Willebrand factor (VWF) and factor...